Clinical Trials on CLL, Refractory

Total 435894 results

National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Myelodysplastic Syndromes

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With Multilineage Dysplasia | Refractory Anemia With Excess Blasts in Transformation | Refractory Anemia...

United States
Case Comprehensive Cancer Center

Completed

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Thrombocytopenia | Chronic Myelomonocytic Leukemia | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With Multilineage Dysplasia | Refractory Anemia With Ringed Sideroblasts

United States
Boston Children's Hospital

Completed

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT

AML | ALL | Biphenotypic Leukemia | Refractory Anemia | Refractory Cytopenia With Multilineage Dysplasia | Refractory Anemia With Ringed Sideroblasts | Undifferentiated Leukemia | Ref. Cytopenia w Multilineage Dysplasia & Ringed Sideroblasts | Refractory Anemia With Excess Blasts-1 (5-10% Blasts) | Refractory... and other conditions

United States
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes

Unspecified Childhood Solid Tumor, Protocol Specific | Childhood Myelodysplastic Syndromes | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With... and other conditions

United States
Onconova Therapeutics, Inc.

Terminated

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE)

Myelodysplastic Syndrome | MDS | Refractory Anemia With Excess Blasts | RAEB

United States, Spain, Canada, France, Australia, Switzerland, Israel, Japan, Belgium, India, Ireland, United Kingdom, Croatia, Czechia, Poland, Estonia, Germany, Italy, Austria, Hungary, Russian Federation, Sweden
National Cancer Institute (NCI)

Completed

Thalidomide in Treating Patients With Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Anemia With Excess Blasts in Transformation | Refractory Anemia With Ringed...

United States
Samsung Medical Center

Unknown

Patients Who Refractory Cancer Conqueror for Bio New Drug Development Translational Research Establishment

Refractory Cancer

Korea, Republic of
Antisoma Research

Completed

Phase I Safety Study of DMXAA in Refractory Tumors (DART)

Refractory Tumors
Samsung Medical Center

Completed

Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors

Refractory Solid Tumors

Korea, Republic of
Samsung Medical Center

Completed

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Refractory Solid Tumors

Korea, Republic of
First Affiliated Hospital of Zhejiang University

Unknown

Effectivity and Safety of Irreversible Electroporation for Refractory Neoplasms in Liver and Pancreas

Refractory Neoplasms

China
SCRI Development Innovations, LLC
Bayer

Completed

Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors

Refractory Malignancy

United States
Samsung Medical Center

Completed

Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer

Refractory Cancer

Korea, Republic of
Scottsdale Healthcare
Translational Genomics Research Institute

Completed

Molecular Profiling Protocol (SCRI-CA-001)

Refractory Cancer

United States
National University Hospital, Singapore
Otsuka Pharmaceutical Co., Ltd.

Unknown

Phase IIa Dose-Expansion and Biomarker Study of OPB-111077

NPC | Refractory Tumor

Singapore
Samsung Medical Center

Completed

Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors

Refractory Solid Tumors

Korea, Republic of
First Affiliated Hospital of Zhejiang University

Unknown

Effectivity and Safety of Endoscopic Ultrasonography-guided Laser Ablation for Refractory Neoplasms

Refractory Neoplasms

China
University of Southern California

Terminated

Oral NRX 194204 in Patients With Refractory Malignancies

Refractory Malignancies

United States
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI); Novartis Pharmaceuticals

Completed

Phase I Study of Patupilone and RAD001

Refractory Malignancy

United States
The First Affiliated Hospital of Xiamen University

Recruiting

Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression

Refractory Solid Tumor

China
The First Affiliated Hospital of Xiamen University

Recruiting

Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors

Refractory Solid Tumor

China
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

AOH1996 for the Treatment of Refractory Solid Tumors

Refractory Malignant Solid Neoplasm

United States
Samsung Medical Center

Completed

Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors

Refractory Solid Tumors

Korea, Republic of
Dr. Tapas K. Das Gupta

Completed

Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment

Refractory Solid Tumors

United States
AVEO Pharmaceuticals, Inc.

Completed

A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients

Advanced Cancer | Refractory Cancer

United States
University of Zurich
University Hospital Inselspital, Berne; Swiss Paraplegic Centre Nottwil; Cantonal...

Completed

Sacral Neuromodulation for Neurogenic LUT Dysfunction

Refractory Neurogenic LUTD

Switzerland
First Affiliated Hospital of Zhejiang University

Unknown

Effectivity and Safety of Ultrasound-guided Percutaneously Laser Ablation for Refractory Neoplasms

Refractory Neoplasms

China
Case Comprehensive Cancer Center
Florida International University; Community Foundation of Broward

Recruiting

Individualized Treatments in Adults With Relapsed/Refractory Cancers

Relapsed Cancer | Refractory Cancer

United States
M.D. Anderson Cancer Center

Recruiting

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

Refractory Solid Tumors

United States
PharmaEngine

Completed

Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors

Refractory Solid Tumors

Taiwan
Samsung Medical Center

Completed

Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors

Refractory Solid Tumors

Korea, Republic of
Samsung Medical Center

Withdrawn

Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors

Refractory Solid Tumors

Korea, Republic of
Myrexis Inc.

Completed

Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors

Refractory Solid Tumors

United States
National Institute of Cancerología
National Council of Science and Technology, Mexico; Psicofarma S.A. de C.V.

Completed

A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors

Refractory Solid Tumors

Mexico
Madeline Fields

Recruiting

The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy

Drug Resistant Epilepsy | Refractory Epilepsy | Medically Refractory Epilepsy

United States
Nantes University Hospital

Withdrawn

Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL (RITEPRALL)

CD22+ Relapsed/Refractory B-ALL

France
Stanford University
Amgen; Pediatric Oncology Experimental Therapeutics Investigators' Consortium

Completed

Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children (POE14-01)

Refractory Leukemia | Refractory Solid Tumors | Relapsed Solid Tumors | Relapsed Leukemia

United States, Canada
Centre Hospitalier Universitaire de Nice

Unknown

Efficiency and Safety of a Procedural Sedation by Propofol on Terminally Ill Patients With Refractory Pain (PROPOPAL2)

Refractory Pains
National Health Research Institutes, Taiwan
National Cheng-Kung University Hospital

Recruiting

Neoantigen Derived DCs as Cancer Treatment

Solid Tumor | Refractory Tumor

Taiwan
Second Affiliated Hospital of Soochow University

Recruiting

Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

Advanced Refractory Solid Tumors

China
CStone Pharmaceuticals
Bayer

Completed

A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors

Advanced Refractory Solid Tumors

Australia
Eli Lilly and Company

Completed

Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors

Cancer | Refractory Solid Tumor

United States
SCRI Development Innovations, LLC
Novartis

Completed

PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies

Advanced Malignancies | Refractory Malignancy

United States
National Cancer Institute (NCI)

Completed

Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndromes | Refractory Anemia With Excess Blasts | Refractory Anemia With Excess Blasts in Transformation

United States
Haisco Pharmaceutical Group Co., Ltd.

Recruiting

A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-Cell Malignancies

China, Australia
Minghui Pharmaceutical (Shanghai) LTD

Recruiting

This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-cell Malignancies

China
Gilead Sciences

Completed

Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-cell Malignancies

France, United Kingdom
Ruijin Hospital
UTC Therapeutics Inc.

Recruiting

Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors (Amaretto)

Refractory Malignant Solid Neoplasm

China
Ruijin Hospital

Recruiting

Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation

Refractory Solid Tumors

China
Samsung Medical Center

Completed

Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors

Refractory Solid Tumors

Korea, Republic of

Clinical Trials on CLL, Refractory

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations